Anti-Spike Protein [CV1]

Absolute Antibody

Anti-Spike Protein [CV1]

9

This antibody is recommended for diagnosis and/or treatment of SARS CoV 2 or 2019-nCoV. CV1 binds an epitope outside the SARS CoV 2 RBD was found to be weakly neutralizing (IC50=15microg/ml). ELISA was used to confirm the binding of SARS CoV 2 positive serum samples to the entire ectodomain and the receptor binding domain of the spike protein. Specific binding of the mAb to SARS CoV 2 to ectodomain was confirmed with biolayer interferometry. Phycoerythrin labelled mAb was used to stain 293E cells transfected with wild type SARS CoV 2 and were analysed by flow cytometry (Seydoux et al., 2020).

Flow Cytometry, ELISA, Neutralisation/Blocking

Research Use Only

Monoclonal

CV1

S

surface glycoprotein

GU280_gp02, spike glycoprotein, surface glycoprotein

Mouse

Spike glycoprotein

This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Virus

-20°C,2°C to 8°C

41116161